Special Issue "TP53 in Solid Tumors and Hematological Malignancies"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 September 2021) | Viewed by 7421
Somatic mutations in the TP53 gene are one of the most frequent alterations in human cancers, mostly consisting of single-base substitutions distributed throughout the coding sequence, and are considered potential prognostic and predictive markers, as well as targets for pharmacological intervention.
In solid tumors and hematological malignancies, the frequency of TP53 mutations is relatively low compared to other tumors. Nevertheless, incidence increases in some cases with disease progression and is associated with a poor prognosis. Several therapeutic approaches have been tested or are currently in clinical development, aiming to target the TP53 pathway, either by blocking its interaction with MDM2 or by restoring the function of the altered protein. However, in TP53 mutated cases, an effective therapeutic option is still lacking.
This Special Issue will be focused on mechanisms of deregulation of TP53 and consequent prognostic impact in solid tumors and hematological malignancies, including acute and chronic leukemias, multiple myeloma, myelodisplastic syndromes and lymphomas, as well as the therapeutic options to interact with the TP53 pathway, highlighting future perspectives for improving treatment and cure rates in such aggressive diseases.
Dr. Cristina Papayannidis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- myelodisplastic syndromes
- multiple myeloma
- target therapy